Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 23%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech is poised for success due to its strong pipeline of innovative drugs, such as the promising BNT326 and pumitamig, which have shown impressive clinical results in multiple cancer indications. The company's strategic partnerships and collaborations also provide additional potential for future growth and development. Despite some potential risks, BioNTech's strong financial position, upcoming data updates, and potential for becoming a leader in the field of immuno-oncology make it an attractive investment opportunity for investors.

Bears say

BioNTech is currently overvalued, with risks including negative data for several of its key pipeline drugs, slower-than-expected market uptake, and a potential for long-term dilution risk. Despite BNT326 showing promising results in comparisons to competitors, there are still concerns about full enrollment in confirmatory Phase 3 studies and potential impacts from more efficacious treatment options. Additionally, the company's reliance on partnerships and potential for failure to advance other programs in a timely manner add to the overall risk profile of the stock.

BioNTech SE (BNTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 23% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 13 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $133.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $133.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.